Pharmaceuticals and Advertising Lawyers in China

A pharmaceutical advertising review starts with what the product legally is and whether the communication is advertising at all. Prescription and non-prescription drugs, medical devices, health foods, special medical-purpose foods, ordinary foods, cosmetics, disease education, scientific exchange, investor communications, patient support, and online sales content do not share one approval or claim framework. The registered label or instructions, intended audience, placement, and commercial purpose must be mapped before creative approval.

Questions that change the route

What product and communication are involved?

Confirm registration or filing status, approved name and holder, prescription status, indication or permitted function, label and instructions, lifecycle changes, intended audience, objective, format, speaker, sponsor, and whether the content is branded, comparative, educational, scientific, promotional, or transactional.

Does the claim stay within the approved basis?

Substantiate efficacy, safety, onset, duration, superiority, statistics, quotations, patient experience, disease references, and visuals; test required warnings and approval numbers; and screen guarantees, endorsements, disguised promotion, off-label implications, prohibited audiences, and omitted risk context.

Who controls approval and distribution?

Map the marketing authorization holder or other responsible entity, advertiser, agency, publisher, platform, influencer or speaker, provincial advertising review, content version, approval validity, media plan, targeting, archiving, monitoring, takedown, complaint, adverse-event, and corrective-action processes.

Evidence to organize first

• Product registration or filing, approved label and instructions, classification and prescription status, advertising approval, variations, and current regulatory correspondence
• Final and redline copy, images, video, landing pages, links, keywords, audience and targeting settings, references, substantiation, translations, warnings, approval number, and publication dates
• Role and approval matrix, agency and platform contracts, medical-legal-regulatory review, version history, dissemination records, monitoring, complaints, safety escalation, takedown, and remediation log

Official orientation sources: Drug Administration Law · Advertising Law (2021 revision) · Interim measures for advertising review of drugs and other regulated health products. Source check: 6 October 2026.